123 related articles for article (PubMed ID: 10664921)
1. Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient.
el-Yazigi A; Ezzat A; Berry J; Raines DA; Yusuf A; al-Rawithi S; Legayada ES
J Clin Pharmacol; 2000 Feb; 40(2):153-60. PubMed ID: 10664921
[TBL] [Abstract][Full Text] [Related]
2. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness of prolonged oral therapy with low-dose etoposide in patients aged 85 years and over with non-Hodgkin's lymphoma].
Niitsu N; Nakayama M; Umeda M
Nihon Ronen Igakkai Zasshi; 1997 Apr; 34(4):263-6. PubMed ID: 9212679
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
7. Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia.
Shaklai S; Bairey O; Blickstein D; Prokocimer M; Hadar H; Lahav M; Sulkes J; Shaklai M
Cancer; 1996 Jun; 77(11):2313-7. PubMed ID: 8635101
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-Hodgkin's lymphoma.
Higa GM; Sarkar MA; DeVore RF
Pharmacotherapy; 1999 Jan; 19(1):101-7. PubMed ID: 9917083
[TBL] [Abstract][Full Text] [Related]
10. Chronic administration of etoposide in the treatment of non-Hodgkin's lymphoma.
Hainsworth JD
Leuk Lymphoma; 1993; 10 Suppl():65-72. PubMed ID: 8481673
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
Vaughan WP; Kris E; Vose J; Bierman PJ; Gwilt P; Armitage JO
J Clin Oncol; 1995 May; 13(5):1089-95. PubMed ID: 7738614
[TBL] [Abstract][Full Text] [Related]
12. Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study.
Osby E; Liliemark E; Björkholm M; Liliemark J
Med Oncol; 2001; 18(4):269-75. PubMed ID: 11918453
[TBL] [Abstract][Full Text] [Related]
13. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease.
Copelan EA; Ceselski SK; Ezzone SA; Lasky LC; Penza SL; Bechtel TP; Klein JL; Hehmeyer DM; Scholl MD; Marshall DD; Elder PJ; Risley GL; Avalos BR
J Clin Oncol; 1997 Feb; 15(2):759-65. PubMed ID: 9053502
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
Foran JM; Oscier D; Orchard J; Johnson SA; Tighe M; Cullen MH; de Takats PG; Kraus C; Klein M; Lister TA
J Clin Oncol; 1999 May; 17(5):1574-9. PubMed ID: 10334546
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of oral etoposide phosphate.
Sessa C; Zucchetti M; Cerny T; Pagani O; Cavalli F; De Fusco M; De Jong J; Gentili D; McDaniel C; Prins C
J Clin Oncol; 1995 Jan; 13(1):200-9. PubMed ID: 7799021
[TBL] [Abstract][Full Text] [Related]
16. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).
Davidson A; Gowing R; Lowis S; Newell D; Lewis I; Dicks-Mireaux C; Pinkerton CR
Eur J Cancer; 1997 Oct; 33(11):1816-22. PubMed ID: 9470839
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients.
Chen CL; Rawwas J; Sorrell A; Eddy L; Uckun FM
Leuk Lymphoma; 2001 Jul; 42(3):317-27. PubMed ID: 11699396
[TBL] [Abstract][Full Text] [Related]
19. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.
Rosenfeld CS; Przepiorka D; Schwinghammer TL; Buck DS; Bloom EJ; Shadduck RK
Exp Hematol; 1991 Jun; 19(5):317-21. PubMed ID: 2026183
[TBL] [Abstract][Full Text] [Related]
20. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen.
Sparano JA; Wiernik PH; Strack M; Leaf A; Becker NH; Sarta C; Carney D; Elkind R; Shah M; Valentine ES
Leuk Lymphoma; 1994 Jul; 14(3-4):263-71. PubMed ID: 7950915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
